Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-803-0 | CAS number: 88-14-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- significant methodological deficiencies
- Justification for type of information:
- Peer-reviewed study of acceptable quality, with the following methodological deficiencies
Data source
Reference
- Reference Type:
- publication
- Title:
- The comparative chronic toxicities of fumaric, tartaric, oxalic and maleic acids
- Author:
- Fitzhugh OG, Nelson AA
- Year:
- 1 947
- Bibliographic source:
- Fitzhugh OG, Nelson AA
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: As mentioned below
- Principles of method if other than guideline:
- The study was a chronic exposure feeding study (conducted prior to development of the
guidelines), limited to the evaluation of body weight, food consumption and histopathology of the
main organs - GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Fumaric acid
- EC Number:
- 203-743-0
- EC Name:
- Fumaric acid
- Cas Number:
- 110-17-8
- Molecular formula:
- C4H4O4
- IUPAC Name:
- Fumaric acid
- Test material form:
- solid
- Details on test material:
- IUPAC name:(2E)-but-2-enedioic acid
Mol. formula: C4H4O4
Molecular Weight: 116.0716 gm/mol
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Osborne-Mendel
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- The animals were male and female weanling rats (21-days) of the Osborn-Mendel strain. All
animals were kept in individual cages in a room with temperature and humidity controlled for the
duration of the experiment. Animals were given free access to their respective diets and water.
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- other: cod liver oil added to moisten diet
- Details on oral exposure:
- Weanling rats (21 days) were fed diets containing fumaric acid for two years. The basic diet
consisted of ground commercial rat biscuits with 1% added cod-liver oil. Fumaric acid was mixed
with the basic diet using a rotary batch mixer. - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- No data
- Duration of treatment / exposure:
- 2 years
- Frequency of treatment:
- Ad libitum in feed
Doses / concentrationsopen allclose all
- Remarks:
- 0, 0.1, 0.5, 0.8 and 1.2% nominal in diet
- Remarks:
- 0, 0.5, 1.0, and 1.5% nominal in diet
- No. of animals per sex per dose:
- Experiment 1 (0, 0.1, 0.5, 0.8 and 1.2%): 12 males and 12 females per group.
Experiment 2 (0, 0.5, 1.0 and 1.5%): 12 males - Control animals:
- yes, plain diet
- Details on study design:
- Two experiments were conducted concurrently, employing two different dosing regimens. The first experiment included both male and female rats, exposed to 0, 0.1, 0.5, 0.8 and 1.2% fumaric acid in the diet. The second experiment was conducted in order to compare the toxicities of fumaric and maleic acids more closely; male rats were fed diets containing 0, 0.5, 1.0 and 1.5% fumaric or maleic acid.
- Positive control:
- None
Examinations
- Observations and examinations performed and frequency:
- Individual animal weights and food consumption were determined at weekly intervals.
- Sacrifice and pathology:
- Gross pathology and histopathology of lung, heart, liver, spleen, pancrease, stomach, small intestine, kidney, adrenal and testis.
Additional structures examined by histopathology include colon, bone marrow, leg bones, leg muscles, lymph nodes, uterus, ovary, thyroid and parathyroid. - Other examinations:
- None
- Statistics:
- No details
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Mortality in the high dose group was significant but low mortality rates evident in lower dose groups (detailed information not provided in study report)
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
Mortality in the high dose group was significant but low mortality rates evident in lower dose groups (detailed information not provided in study report)- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- weight gains recorded for males and females at each dose level showed no treatment related effects (data were presented for 1 year only)
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
Food consumption over the first 26 weeks of the study and second 26 weeks were compared for each treatment group. No statistically significant changes observed (no detailed information is included in the study report).- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Sporadic findings reported but no treatment relationship established
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Details on results:
- At two years, there were only 2 animals living on 1.5% fumaric acid.; other dose levels had no effect on mortality rate. Animals fed 1.5% fumaric acid showed more atrophy of the testis and 2 rats fed 0.5% and 1.0% fumaric acid showed phlegmonous gastritis.
Effect levels
- Dose descriptor:
- NOEL
- Effect level:
- ca. 600 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Low incidence of mortality seen at a dose level of 1.5%
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Mean gain in weight of rats fed fumaric acid for a year (data from a previous experiment is also included)
Test material | Dosage (%) | No. of animals | Sex | Mean gain in weight (g) | Standard error of mean (+ g) |
Fumaric acid | 0.1 | 11 | M | 452.9 | 19.0 |
0.1 | 10 | F | 288.0 | 10.0 | |
0.5 | 10 | M | 444.4 | 20.7 | |
0.5 | 12 | F | 269.7 | 9.6 | |
0.8 | 9 | M | 429.6 | 11.0 | |
0.8 | 12 | F | 265.2 | 5.7 | |
1.0 | 10 | M | 468.8 | 25.9 | |
1.2 | 11 | M | 466.9 | 14.6 | |
1.2 | 12 | F | 280.0 | 10.2 | |
1.5 | 7 | M | 459.9 | 23.2 | |
Control | 31 | M | 464.9 | 13.4 | |
22 | F | 274.4 | 9.8 |
Applicant's summary and conclusion
- Conclusions:
- Signs of toxic effects were observed when rats were fed fumaric acid at high dietary concentrations - 1.5%.
Toxic effects occurred in rats fed diets containing 1.5% fumaric acid for two years. An increase in mortality rate and more atrophy of the testis were seen in rats fed 1.5% fumaric acid. Inanition seems at least partly responsible for atrophy of the testis.
No adverse effects on reproductive organs were reported in a concurrent study using female rats administered up to 1.2% fumaric acid in the diet for 2 years.
The NOAEL was 1.2% or circa 600 mg/kg bw/day.
A concurrent study conducted in a similar manner with male and female rats showed no adverse effects on reproductive organs after administration of up to 1.2% fumaric acid in the diet for 2 years. Based on the low incidence of mortality of male rats, 1.2% is very near a NOAEL for chronic exposure to fumaric acid (600 mg/kg bw). The 1.2% NOAEL (600 mg/kg bw/day) derived from the available long term rat toxicity data was confirmed as the appropriate point of departure by two reviews - The International Programme on Chemical Safety (WHO 1975 Food Additive Series 6) report and the findings ofthe European Commission DG C Report of the Scientific Committee on animal nutrition on the safety of fumaric acid (SCAN, 2003).
In the SCAN report, a safe use was established in piglets in the field at circa 1000 mg/kg bw/day and circa 2000 mg/kg bw/day in experimental data. For human psoriatic patients the safe use was 0.9g fumaric acid equivalent/d or circa 15 mg/kg bw/day.
The WHO report contains confirmation of the study in which groups of rats were dosed at 1.2% fumaric acid without adverse toxicological effects. - Executive summary:
Groups of 12 male and 12 female rats were fed 0, 0.1, 0.5, 0.8 or 1.2% fumaric acid, and groups of 12 male rats were fed 0, 0.5, 1 or 1.5% fumaric acid for 2 years.A very slight increase in mortality rate and some testicular atrophy was observed after administration of 1.5% fumaric acid (approximately 750 mg/kg bw/day). Gross and microscopic examination of major organs revealed no abnormalities. Two rats receiving 1% or 0.5% had stomach inflammation. The authors of this study concluded that inanition was partly responsible for testicular atrophy. In the study with female rats, no adverse effects on reproductive organs were observed after administration of up to 1.2% fumaric acid in the diet. Based on the low incidence of mortality of male rats, 1.2% is very near a NOAEL for chronic exposure to fumaric acid (600 mg/kg bw). The 1.2% NOAEL (600 mg/kg bw/day) derived from the available long term rat toxicity data was confirmed as the appropriate point of departure by two reviews - The International Programme on Chemical Safety (WHO 1975 Food Additive Series 6) report and the findings of the European Commission DG C Report of the Scientific Committee on animal nutrition on the safety of fumaric acid.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.